An open-label study of escitalopram in body dysmorphic disorder

International Clinical Psychopharmacology

Volumn 21, Issue 3, 2006, Pages 177-179

  Phillips, Katharine A ^a  

^a BUTLER HOSPITAL   (United States)

Author keywords

Body dysmorphic disorder; Delusional disorder; Dysmorphophobia; Escitalopram; Pharmacotherapy; Treatment

Indexed keywords

ESCITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BLURRED VISION; BODY DYSMORPHIC DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; DELUSION; DEPRESSION; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INSOMNIA; JAW DISEASE; MALE; NAUSEA; NERVOUSNESS; OPEN STUDY; PAIN; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT RESPONSE; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; FEMALE; HUMANS; MIDDLE AGED; NAUSEA; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SLEEP INITIATION AND MAINTENANCE DISORDERS; SOMATOFORM DISORDERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33646713654     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000194378.65460.ef     Document Type: Article

References (16)

1. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association.
2. Eisen JL, Phillips KA, Baer L, Beer DA, Atala KD, Rasmussen SA (1998). The Brown Assessment of Beliefs Scale: reliability and validity. Am J Psychiatry 155:102-108.
3. Endicott J, Nee J, Harrison W, Blumenthal R (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 29:321-326.
4. First MB, Spitzer RL, Gibbon M, Williams JBW (2002). Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edn (SCID-I/P). New York, New York: Biometrics Research, New York State Psychiatric Institute.
5. Hollander E, Allen A, Kwon J, Aronowitz B, Schmeidler J, Wong C, et al. (1999). Clomipramine versus desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry 56:1033-1039.
6. Keller MB, Lavori PW, Friedman B, Nielsen E, Endicott J, McDonald-Scott P, et al. (1987). The Longitudinal Interval Follow-up Evaluation: a comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry 44:540-548.
7. Miller IW, Bishop S, Norman WH, Maddever H (1985). The modified Hamilton Rating Scale for depression: reliability and validity. Psychiatry Res 14:131-142.
8. National Institute of Mental Health (1985). Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 21:839.
9. Perugi G, Giannotti D, Di Vaio S, Frare F, Saettoni M, Cassano GB (1996). Fluvoxamine in the treatment of body dysmorphic disorder (dysmorpho-phobia). Int Clin Psychopharmacol 11:247-254.
10. Phillips KA (2001). Body dysmorphic disorder. In: Phillips KA, editor: Somatoform and factitious disorders. Washington, DC: American Psychiatric Publishing.
11. Phillips KA (2002). Pharmacologic treatment of body dysmorphic disorder: review of the evidence and a recommended treatment approach. CNS Spectrums 7:453-460.
12. Phillips KA, Najjar F (2003). An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry 64:715-720.
13. Phillips KA, Hollander E, Rasmussen SA, Aronowitz BR, DeCaria C, Goodman WK (1997). A severity rating scale for body dysmorphic disorder. Psychopharmacol Bull 33:17-22.
14. Phillips KA, Dwight MM, McElroy SL (1998). Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry 59:165-171.
15. Phillips KA, Albertini RS, Rasmussen SA (2002). A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry 59:381-388.
16. Ware JE Jr (1993). SF-36 health survey manual and interpretation guide. Boston, Massachusetts: The Health Institute, New England Medical Center.